Review
English
Jagannadha Rao Peela 1, Abdalla M. Jarari 1, Abdul Hai 1, Avinaash K. Rawal 1, Shoba Devi Kolla 2, Shakila Sreekumar 3, Lokesh Khurana 4, Narsinga Rao Sidhanathi 5
1-Department of Biochemistry Faculty of Medicine Al-Arab Medical University Benghazi, Libya 2-Department of Biochemistry, Andhra Medical College, Visakhapatnam, India 3-Department of Biochemistry, Faculty of Medicine,Al-Tadah University, Sirt, Libya 4-Center for Diabetes, Obesity, and Cholesterol Disorders (C-DOC), Diabetes Foundation (India), SDA, New Delhi 110016, India 5-Department of Medicine, Andhra Medical College, Visakhapatnam, India
IJMBS 2010, 2(5):190-197
Abstract
Acute coronary syndromes (ACS) represent a range of ischemic heart disease from unstable angina to myocardial infarction (MI) and may involve large areas of cardiac necrosis. The symptomatic manifestations of an acute MI (AMI) may be varied and ECG is also non-diagnostic in about 50% of cases, which poses a risk for potential misdiagnosis. Biochemical markers and cardiac enzymes like transaminases and creatine kinase (CK) were used early as diagnostic markers, and gradually improved markers like creatine kinase MB (CK-MB) evolved and are used to diagnose AMI and assess cardiac damage. But their non-specificity has been an issue and has led to introduction of more specific and sensitive cardiac biomarkers, e.g troponins. Troponins are quite efficacious and better than earlier markers, and they not only diagnose, but also help in risk assessment and therapeutic decision-making. However, the search for an ideal cardiac marker is still on, though troponins seem to have lot of qualities of an ideal marker.1
Keywords: Cardiac BioMarkers: The Troponins and CK- MB
Link/DOI: http://journals.sfu.ca/ijmbs/index.php/ijmbs/article/view/98/231